Pfizer Inc
NYSE:PFE
Pfizer Inc
Cash from Operating Activities
Pfizer Inc
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Pfizer Inc
NYSE:PFE
|
Cash from Operating Activities
$8.7B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Operating Activities
$23.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Operating Activities
$13.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
17%
|
CAGR 10-Years
12%
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Operating Activities
$14.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
Zoetis Inc
NYSE:ZTS
|
Cash from Operating Activities
$2.4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
20%
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Operating Activities
$3.7B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-4%
|
See Also
What is Pfizer Inc's Cash from Operating Activities?
Cash from Operating Activities
8.7B
USD
Based on the financial report for Mar 31, 2024, Pfizer Inc's Cash from Operating Activities amounts to 8.7B USD.
What is Pfizer Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-7%
Over the last year, the Cash from Operating Activities growth was -64%. The average annual Cash from Operating Activities growth rates for Pfizer Inc have been -18% over the past three years , -11% over the past five years , and -7% over the past ten years .